Horse Serum Formulation

Human Endothelial Growth Medium-Serum Free Formulation 1 (EGM-SF1)
cAP-02-SF1	Angio Proteomie	500ml	EUR 133.65

Horse Serum Laboratories manufactures the horse serum formulation reagents distributed by Genprice. The Horse Serum Formulation reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Horse Serum. Other Horse products are available in stock. Specificity: Horse Category: Serum Group: Formulation

Serum albumin
SAB	1mg	EUR 2640

Serum albumin
SAB	1mg	EUR 2640

Serum albumin
SAB	1mg	EUR 2640

Serum albumin
SAB	1mg	EUR 2640

Goat serum
Abbexa	10 nmol	EUR 287.5

Goat serum
Abbexa	5 nmol	EUR 237.5

Alpaca Serum
Abbexa	10 nmol	EUR 1462.5

Formulation information

Lificiguat (YC-1) Liposomes, Formulation FNT8P.2
DLL-0016-A1-10ML	LipExoGen	10mL	EUR 2995
Description: PEGylated liposomes containing HIF-1α inhibitor Lificiguat (YC-1). Lificiguat (YC-1) is an inhibitor of Hypoxia-inducible factor-1 alpha (HIF-1 alpha). YC-1 also activates soluble guanylyl cyclase (sGC) in (NO)-independent manner. Lificiguat (YC-1) is insoluble in aqueous media. This product is a pre-formulated liposomal version of Lificiguat which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1A-100MG	LipExoGen	10 mL	EUR 2995
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1A-10MG	LipExoGen	1 mL	EUR 595
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1A-25MG	LipExoGen	2.5 mL	EUR 995
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1B-100MG	LipExoGen	10 mL	EUR 3195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1B-10MG	LipExoGen	1 mL	EUR 795
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1B-25MG	LipExoGen	2.5 mL	EUR 1195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1C-100MG	LipExoGen	10 mL	EUR 3195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1C-10MG	LipExoGen	1 mL	EUR 795
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1C-25MG	LipExoGen	2.5 mL	EUR 1195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1D-100MG	LipExoGen	10 mL	EUR 3195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1D-10MG	LipExoGen	1 mL	EUR 795
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1D-25MG	LipExoGen	2.5 mL	EUR 1195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1E-10MG	LipExoGen	1 mL	EUR 795
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1E-25MG	LipExoGen	2.5 mL	EUR 1195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1E-50MG	LipExoGen	5 mL	EUR 3195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Alternate BTEX Standard Formulation (High Level) - 1ML
BTEX-100H	Scientific Laboratory Supplies	1ML	EUR 56.7